| [1] | Gege TIAN, Enrui XIA, Suyan ZHANG, Shunzhen ZHAGN, Furong XU. Research advances in traditional Chinese medicine in improving nonalcoholic steatohepatitis by regulating the Toll-like receptor 4/nuclear factor-kappa B signaling pathway[J]. Journal of Clinical Hepatology, 2021, 37(12): 2957-2962. doi: 10.3969/j.issn.1001-5256.2021.12.047 |
| [2] | Zheng Yang, Wang JiaRu, Liu LuLu, Wang JiaHui, Zhao TieJian. Molecular mechanism of the anti-liver fibrosis effect of curcumol: An analysis based on the TLR4/NF-κB signaling pathway[J]. Journal of Clinical Hepatology, 2020, 36(7): 1508-1513. doi: 10.3969/j.issn.1001-5256.2020.07.013 |
| [3] | He WeiLi, Yang XiaoYue, Zhang AiJun, Wang XiaoYang, Wang YaJun, Zhao Fan, Xu GuangFu. Association of TLR4 gene polymorphism with susceptibility to and prognosis of hepatitis B virus-related primary liver cancer[J]. Journal of Clinical Hepatology, 2020, 36(7): 1540-1544. doi: 10.3969/j.issn.1001-5256.2020.07.018 |
| [4] | Cui HaiXia, Jin ChunMei, Wu ZhengXie, Jin AiHua, Zhang MeiLan. Correlation of miRNA-181c expression in peripheral blood mononuclear cells with interferon-γ,chemokine( C-X-C motif) ligand 10,and Toll-like receptor 4 in children with autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2020, 36(10): 2236-2240. doi: 10.3969/j.issn.1001-5256.2020.10.015 |
| [5] | Huang Rong, Ni JiaJia, Gao Yi. The association between the intestinal microbiota-lipopolysaccharide-Toll-like receptor 4 axis and hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2018, 34(6): 1325-1328. doi: 10.3969/j.issn.1001-5256.2018.06.041 |
| [6] | Wang Yan, Cui LiJian, Xiao HongLi, Wang GuoXing, Yin ChengHong. Effect of angiotensin 1-7 on the TLR4/NF-κB pathway in cerulein-induced pancreatic acinar cells[J]. Journal of Clinical Hepatology, 2016, 32(11): 2146-2150. doi: 10.3969/j.issn.1001-5256.2016.11.029 |
| [7] | Fan WenHai, Chen QingFeng. Research advances in association between Toll- like receptor 4 and hepatitis B[J]. Journal of Clinical Hepatology, 2016, 32(3): 584-587. doi: 10.3969/j.issn.1001-5256.2016.03.041 |
| [8] | Shen Min, Fan HuaiYan, Wei Jia. Research progress in relationship between TLR4 and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2015, 31(4): 630-634. doi: 10.3969/j.issn.1001-5256.2015.04.038 |
| [9] | Zhang QiuNan, Xiao Ying, Miao RuiXin, Zhang YaQing, Zhu Ying. Changes in intestinal flora in nonalcoholic fatty liver disease: their correlation with insulin resistance index,tumor necrosis factor- α,and interleukin- 6[J]. Journal of Clinical Hepatology, 2015, 31(7): 1078-1081. doi: 10.3969/j.issn.1001-5256.2015.07.019 |
| [10] | Wu Qin, Meng FanPing, Ma XueMei, Jin Bo, Shen LiJun, Wu LiBing, Chu JinDong, Lai WenHui, Han JingJing, Li HanWei. Analysis of association between different HCV genotypes and serum interleukin-17, interleukin-6, and vitamin D in patients with HCV-related cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(11): 1849-1852. doi: 10.3969/j.issn.1001-5256.2015.11.019 |
| [11] | Wu YuJing, Guo JinSheng. Hepatic stellate cells,Toll-like receptor 4 signaling pathway,and inflammatory fibrotic microenvironment in the development of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2015, 31(6): 876-879. doi: 10.3969/j.issn.1001-5256.2015.06.012 |
| [12] | Li Xia, Shi YongYu. Correlation between interleukin-6 and primary hepatocellular carcinoma: a meta-analysis[J]. Journal of Clinical Hepatology, 2015, 31(6): 936-942. doi: 10.3969/j.issn.1001-5256.2015.06.026 |
| [13] | Zhao XiaoLing, Zhang YongGang. Clinical efficacy of ribavirin combined with different doses of interferon α- 2b in patients with chronic hepatitis C genotypes 2 and 3[J]. Journal of Clinical Hepatology, 2013, 29(10): 780-783. doi: 10.3969/j.issn.1001-5256.2013.10.014 |
| [14] | Jiang PingPing, Zhang Quan, Wang YuPing, Wang Hui, Cheng MingLiang. Preventive effects of blueberry on hepatic injury by downregulating the expression of TLR4[J]. Journal of Clinical Hepatology, 2012, 28(5): 380-382+394. |
| [15] | Zuo WeiZe, Xu ChunMei, Shen LanChao. Changes in serum level of interleukin-32 and interleukin-6 in patients with chronic hepatitis B virus infection and its clinical significance[J]. Journal of Clinical Hepatology, 2011, 27(4): 408-410+413. |
| [16] | Wang Xu, Yuan ChengMin, Wu AnZhao, Lu Yong, Zhao YuJuan. The observation of anti-viral effect of matrine combined with interferon α-2b on the chronic hepatitis B patients with mild transaminase elevations[J]. Journal of Clinical Hepatology, 2011, 27(5): 488-489+502. |
| [17] | Shi QingFeng, Song JiKui, Zhang YingXin, Yuan JianGuo, Wang SiKui, Li QingFang, Zhao HongKui. Study on the expression of HLA-DR/CD69 on CD4+/CD8+T cells in the treatment of HBeAg-positive chronic hepatitis B with interferon alfa-2b[J]. Journal of Clinical Hepatology, 2011, 27(12): 1285-1287+1300. |
| [18] | Jin Rui, Zhang ShiBin, Bian XinQu, Lu ChengZhen, Liu ZhongSheng, Guo XinHui. Clinical study of IFNα-2b alone or in combination with lamivudine for HBeAg positive chronic hepatitis B[J]. Journal of Clinical Hepatology, 2011, 27(6): 617-619. |
| [19] | Wang RuiKe, Liu XiuZhen, Zhang GuYun, Li Hong, Sun ZhaoCui, Zhang JinAn. Monitoring the change of interleukin-6 in the alcoholic liver disease and its clinical significance[J]. Journal of Clinical Hepatology, 2005, 21(2): 100-101. |
DownLoad: